Alector to Present at the Barclays Global Healthcare Conference

Rhea-AI Summary

Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on immuno-neurology, announced participation in the Barclays Global Healthcare Conference on March 11, 2021, at 2:25 p.m. ET by COO Shehnaaz Suliman, M.D. A live webcast will be available on Alector's Investors page, with a replay accessible for 30 days post-event. Alector is developing innovative therapies targeting neurodegenerative diseases, utilizing innate immune system programs to address immune dysfunction in conditions like Alzheimer's and frontotemporal dementia. Visit www.alector.com for more information.

SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in a fireside chat at the Barclays Global Healthcare Conference on Thursday, March 11, 2021, at 2:25 p.m. ET.

A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 30 days following the event.

About Alector

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the Company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

Contacts
Media:
Erica Jefferson
Vice President, Communications and Public Affairs
Alector, Inc.
301-928-4650
erica.jefferson@alector.com

1AB
Dan Budwick
973-271-6085
dan@1abmedia.com

or

Investors:
Alector, Inc.
ir@alector.com

FAQ

When is Alector's participation in the Barclays Global Healthcare Conference?

Alector will participate in the Barclays Global Healthcare Conference on March 11, 2021, at 2:25 p.m. ET.

How can I watch Alector's fireside chat at the conference?

You can watch the live webcast of Alector's fireside chat on their 'Events & Presentations' page in the Investors section of their website.

What is Alector's focus in biotechnology?

Alector focuses on immuno-neurology, developing therapies for neurodegenerative diseases by targeting immune dysfunction.

What diseases are targeted by Alector's product candidates?

Alector's product candidates target neurodegenerative diseases such as frontotemporal dementia and Alzheimer's disease.

Where is Alector, Inc. headquartered?

Alector, Inc. is headquartered in South San Francisco, California.